The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)
Background The cytokine transforming growth factor-ß (TGF-ß) is a pivotal contributor to tissue fibrosis and a key cytokine in the pathogenesis of cellular transdifferentiation, epithelial-mesenchymal transition (EMT), and cell adhesion. This study evaluates the effect of decorin, a naturally occurr...
Gespeichert in:
| Veröffentlicht in: | Graefe's archive for clinical and experimental ophthalmology 2011-11, Vol.249 (11), p.1649-1660 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1660 |
|---|---|
| container_issue | 11 |
| container_start_page | 1649 |
| container_title | Graefe's archive for clinical and experimental ophthalmology |
| container_volume | 249 |
| creator | Nassar, Khaled Lüke, Julia Lüke, Matthias Kamal, Mahmoud Abd El-Nabi, Effat Soliman, Mahmoud Rohrbach, Martin Grisanti, Salvatore |
| description | Background
The cytokine transforming growth factor-ß (TGF-ß) is a pivotal contributor to tissue fibrosis and a key cytokine in the pathogenesis of cellular transdifferentiation, epithelial-mesenchymal transition (EMT), and cell adhesion. This study evaluates the effect of decorin, a naturally occurring TGF-ß inhibitor, in an experimental rabbit model for proliferative vitreoretinopathy (PVR).
Methods
Traumatic PVR was induced in 50 rabbits divided into ten groups (
n
= 5). One group (GI) reveals a control with no treatment after trauma. Groups (GII–GIV) consisted of subgroups receiving phacovitrectomy at three different time points; (a) at the time of trauma, (b) 1 week following trauma, and (c) 2 weeks following trauma. GIII and GIV received 100 μg or 200 μg decorin, respectively. PVR severity was scored from 0 to 4. The amount of fibrosis was quantified using JMicroVision© software.
Results
The control group GI developed severe PVR with tractional retinal detachment (TRD); (PVR score ≥2) in four rabbits out of five. Vitrectomy had a positive effect (
p
|
| doi_str_mv | 10.1007/s00417-011-1730-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_900769164</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2496639231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-c02aedb45e0dfb41caee688fdb6e3af7406e9b407c60a78c0ac96049c1219f7b3</originalsourceid><addsrcrecordid>eNp1kF1LwzAUhoMobk5_gDdSvNKL6kmbNu2lDL9goMiU3YU0PXUdXVOTtrB_b0qnXgmBwHue88FDyDmFGwrAby0Ao9wHSn3KQ_DTAzKlLIx8DsHqkEyBB9RPwmA1ISfWbsDhYUSPySRweBQwmJJsuUav1j1WXmfR04WXo9KmrD33GoM91m2p66HQOjJ3QaWbrUuHqDG6Kgs0si179PqyNagNtmWtG9mud97V68fb9Sk5KmRl8Wz_z8j7w_1y_uQvXh6f53cLX7Ewbn0FgcQ8YxFCXmSMKokYJ0mRZzGGsuAMYkwzBlzFIHmiQKo0BpYqGtC04Fk4I5fjXHfVV4e2FRvdmdqtFKmzFac0Zg6iI6SMttZgIRpTbqXZCQpikCpGqcJJFYNUkbqei_3gLtti_tvxY9EBwQhYV6o_0fxt_n_qN0Htg1s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>900769164</pqid></control><display><type>article</type><title>The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Nassar, Khaled ; Lüke, Julia ; Lüke, Matthias ; Kamal, Mahmoud ; Abd El-Nabi, Effat ; Soliman, Mahmoud ; Rohrbach, Martin ; Grisanti, Salvatore</creator><creatorcontrib>Nassar, Khaled ; Lüke, Julia ; Lüke, Matthias ; Kamal, Mahmoud ; Abd El-Nabi, Effat ; Soliman, Mahmoud ; Rohrbach, Martin ; Grisanti, Salvatore</creatorcontrib><description>Background
The cytokine transforming growth factor-ß (TGF-ß) is a pivotal contributor to tissue fibrosis and a key cytokine in the pathogenesis of cellular transdifferentiation, epithelial-mesenchymal transition (EMT), and cell adhesion. This study evaluates the effect of decorin, a naturally occurring TGF-ß inhibitor, in an experimental rabbit model for proliferative vitreoretinopathy (PVR).
Methods
Traumatic PVR was induced in 50 rabbits divided into ten groups (
n
= 5). One group (GI) reveals a control with no treatment after trauma. Groups (GII–GIV) consisted of subgroups receiving phacovitrectomy at three different time points; (a) at the time of trauma, (b) 1 week following trauma, and (c) 2 weeks following trauma. GIII and GIV received 100 μg or 200 μg decorin, respectively. PVR severity was scored from 0 to 4. The amount of fibrosis was quantified using JMicroVision© software.
Results
The control group GI developed severe PVR with tractional retinal detachment (TRD); (PVR score ≥2) in four rabbits out of five. Vitrectomy had a positive effect (
p
< 0.05) on PVR development when preformed immediately, however the developed fibrosis was high. The best results were obtained when surgery was used in conjunction with decorin that reduced both the PVR score and fibrosis development significantly (
p
< 0.05). Depending on dosage and time of vitrectomy, PVR could be completely avoided (PVR score = 0) in 16 rabbits out of 30. TRD was prevented in 13 rabbits out of 15 in GIII to 14 rabbits out of 15 in GIV. In decorin-treated eyes, vitrectomy outcome was best when preformed at 1 week after trauma. There were no drug-related toxic effects evident on clinical and histopathological examination.
Conclusions
In conclusion, in this rabbit model of PVR, adjuvant decorin application during vitrectomy effectively reduces fibrosis and TRD development. In conjunction with no obvious histopathological toxicity signs, decorin represents a promising substance to inhibit PVR reactions.</description><identifier>ISSN: 0721-832X</identifier><identifier>EISSN: 1435-702X</identifier><identifier>DOI: 10.1007/s00417-011-1730-9</identifier><identifier>PMID: 21735240</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Animals ; Decorin - therapeutic use ; Disease Models, Animal ; Female ; Fibrosis - prevention & control ; Intravitreal Injections ; Medicine ; Medicine & Public Health ; Ophthalmology ; Phacoemulsification ; Rabbits ; Retina - pathology ; Retinal Detachment - pathology ; Retinal Detachment - prevention & control ; Retinal Disorders ; Transforming Growth Factor beta - antagonists & inhibitors ; Vitrectomy ; Vitreoretinopathy, Proliferative - prevention & control</subject><ispartof>Graefe's archive for clinical and experimental ophthalmology, 2011-11, Vol.249 (11), p.1649-1660</ispartof><rights>Springer-Verlag 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-c02aedb45e0dfb41caee688fdb6e3af7406e9b407c60a78c0ac96049c1219f7b3</citedby><cites>FETCH-LOGICAL-c436t-c02aedb45e0dfb41caee688fdb6e3af7406e9b407c60a78c0ac96049c1219f7b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00417-011-1730-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00417-011-1730-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27904,27905,41468,42537,51299</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21735240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nassar, Khaled</creatorcontrib><creatorcontrib>Lüke, Julia</creatorcontrib><creatorcontrib>Lüke, Matthias</creatorcontrib><creatorcontrib>Kamal, Mahmoud</creatorcontrib><creatorcontrib>Abd El-Nabi, Effat</creatorcontrib><creatorcontrib>Soliman, Mahmoud</creatorcontrib><creatorcontrib>Rohrbach, Martin</creatorcontrib><creatorcontrib>Grisanti, Salvatore</creatorcontrib><title>The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)</title><title>Graefe's archive for clinical and experimental ophthalmology</title><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><description>Background
The cytokine transforming growth factor-ß (TGF-ß) is a pivotal contributor to tissue fibrosis and a key cytokine in the pathogenesis of cellular transdifferentiation, epithelial-mesenchymal transition (EMT), and cell adhesion. This study evaluates the effect of decorin, a naturally occurring TGF-ß inhibitor, in an experimental rabbit model for proliferative vitreoretinopathy (PVR).
Methods
Traumatic PVR was induced in 50 rabbits divided into ten groups (
n
= 5). One group (GI) reveals a control with no treatment after trauma. Groups (GII–GIV) consisted of subgroups receiving phacovitrectomy at three different time points; (a) at the time of trauma, (b) 1 week following trauma, and (c) 2 weeks following trauma. GIII and GIV received 100 μg or 200 μg decorin, respectively. PVR severity was scored from 0 to 4. The amount of fibrosis was quantified using JMicroVision© software.
Results
The control group GI developed severe PVR with tractional retinal detachment (TRD); (PVR score ≥2) in four rabbits out of five. Vitrectomy had a positive effect (
p
< 0.05) on PVR development when preformed immediately, however the developed fibrosis was high. The best results were obtained when surgery was used in conjunction with decorin that reduced both the PVR score and fibrosis development significantly (
p
< 0.05). Depending on dosage and time of vitrectomy, PVR could be completely avoided (PVR score = 0) in 16 rabbits out of 30. TRD was prevented in 13 rabbits out of 15 in GIII to 14 rabbits out of 15 in GIV. In decorin-treated eyes, vitrectomy outcome was best when preformed at 1 week after trauma. There were no drug-related toxic effects evident on clinical and histopathological examination.
Conclusions
In conclusion, in this rabbit model of PVR, adjuvant decorin application during vitrectomy effectively reduces fibrosis and TRD development. In conjunction with no obvious histopathological toxicity signs, decorin represents a promising substance to inhibit PVR reactions.</description><subject>Animals</subject><subject>Decorin - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Fibrosis - prevention & control</subject><subject>Intravitreal Injections</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Phacoemulsification</subject><subject>Rabbits</subject><subject>Retina - pathology</subject><subject>Retinal Detachment - pathology</subject><subject>Retinal Detachment - prevention & control</subject><subject>Retinal Disorders</subject><subject>Transforming Growth Factor beta - antagonists & inhibitors</subject><subject>Vitrectomy</subject><subject>Vitreoretinopathy, Proliferative - prevention & control</subject><issn>0721-832X</issn><issn>1435-702X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kF1LwzAUhoMobk5_gDdSvNKL6kmbNu2lDL9goMiU3YU0PXUdXVOTtrB_b0qnXgmBwHue88FDyDmFGwrAby0Ao9wHSn3KQ_DTAzKlLIx8DsHqkEyBB9RPwmA1ISfWbsDhYUSPySRweBQwmJJsuUav1j1WXmfR04WXo9KmrD33GoM91m2p66HQOjJ3QaWbrUuHqDG6Kgs0si179PqyNagNtmWtG9mud97V68fb9Sk5KmRl8Wz_z8j7w_1y_uQvXh6f53cLX7Ewbn0FgcQ8YxFCXmSMKokYJ0mRZzGGsuAMYkwzBlzFIHmiQKo0BpYqGtC04Fk4I5fjXHfVV4e2FRvdmdqtFKmzFac0Zg6iI6SMttZgIRpTbqXZCQpikCpGqcJJFYNUkbqei_3gLtti_tvxY9EBwQhYV6o_0fxt_n_qN0Htg1s</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>Nassar, Khaled</creator><creator>Lüke, Julia</creator><creator>Lüke, Matthias</creator><creator>Kamal, Mahmoud</creator><creator>Abd El-Nabi, Effat</creator><creator>Soliman, Mahmoud</creator><creator>Rohrbach, Martin</creator><creator>Grisanti, Salvatore</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20111101</creationdate><title>The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)</title><author>Nassar, Khaled ; Lüke, Julia ; Lüke, Matthias ; Kamal, Mahmoud ; Abd El-Nabi, Effat ; Soliman, Mahmoud ; Rohrbach, Martin ; Grisanti, Salvatore</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-c02aedb45e0dfb41caee688fdb6e3af7406e9b407c60a78c0ac96049c1219f7b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Decorin - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Fibrosis - prevention & control</topic><topic>Intravitreal Injections</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Phacoemulsification</topic><topic>Rabbits</topic><topic>Retina - pathology</topic><topic>Retinal Detachment - pathology</topic><topic>Retinal Detachment - prevention & control</topic><topic>Retinal Disorders</topic><topic>Transforming Growth Factor beta - antagonists & inhibitors</topic><topic>Vitrectomy</topic><topic>Vitreoretinopathy, Proliferative - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nassar, Khaled</creatorcontrib><creatorcontrib>Lüke, Julia</creatorcontrib><creatorcontrib>Lüke, Matthias</creatorcontrib><creatorcontrib>Kamal, Mahmoud</creatorcontrib><creatorcontrib>Abd El-Nabi, Effat</creatorcontrib><creatorcontrib>Soliman, Mahmoud</creatorcontrib><creatorcontrib>Rohrbach, Martin</creatorcontrib><creatorcontrib>Grisanti, Salvatore</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nassar, Khaled</au><au>Lüke, Julia</au><au>Lüke, Matthias</au><au>Kamal, Mahmoud</au><au>Abd El-Nabi, Effat</au><au>Soliman, Mahmoud</au><au>Rohrbach, Martin</au><au>Grisanti, Salvatore</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)</atitle><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle><stitle>Graefes Arch Clin Exp Ophthalmol</stitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><date>2011-11-01</date><risdate>2011</risdate><volume>249</volume><issue>11</issue><spage>1649</spage><epage>1660</epage><pages>1649-1660</pages><issn>0721-832X</issn><eissn>1435-702X</eissn><abstract>Background
The cytokine transforming growth factor-ß (TGF-ß) is a pivotal contributor to tissue fibrosis and a key cytokine in the pathogenesis of cellular transdifferentiation, epithelial-mesenchymal transition (EMT), and cell adhesion. This study evaluates the effect of decorin, a naturally occurring TGF-ß inhibitor, in an experimental rabbit model for proliferative vitreoretinopathy (PVR).
Methods
Traumatic PVR was induced in 50 rabbits divided into ten groups (
n
= 5). One group (GI) reveals a control with no treatment after trauma. Groups (GII–GIV) consisted of subgroups receiving phacovitrectomy at three different time points; (a) at the time of trauma, (b) 1 week following trauma, and (c) 2 weeks following trauma. GIII and GIV received 100 μg or 200 μg decorin, respectively. PVR severity was scored from 0 to 4. The amount of fibrosis was quantified using JMicroVision© software.
Results
The control group GI developed severe PVR with tractional retinal detachment (TRD); (PVR score ≥2) in four rabbits out of five. Vitrectomy had a positive effect (
p
< 0.05) on PVR development when preformed immediately, however the developed fibrosis was high. The best results were obtained when surgery was used in conjunction with decorin that reduced both the PVR score and fibrosis development significantly (
p
< 0.05). Depending on dosage and time of vitrectomy, PVR could be completely avoided (PVR score = 0) in 16 rabbits out of 30. TRD was prevented in 13 rabbits out of 15 in GIII to 14 rabbits out of 15 in GIV. In decorin-treated eyes, vitrectomy outcome was best when preformed at 1 week after trauma. There were no drug-related toxic effects evident on clinical and histopathological examination.
Conclusions
In conclusion, in this rabbit model of PVR, adjuvant decorin application during vitrectomy effectively reduces fibrosis and TRD development. In conjunction with no obvious histopathological toxicity signs, decorin represents a promising substance to inhibit PVR reactions.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>21735240</pmid><doi>10.1007/s00417-011-1730-9</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0721-832X |
| ispartof | Graefe's archive for clinical and experimental ophthalmology, 2011-11, Vol.249 (11), p.1649-1660 |
| issn | 0721-832X 1435-702X |
| language | eng |
| recordid | cdi_proquest_journals_900769164 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Animals Decorin - therapeutic use Disease Models, Animal Female Fibrosis - prevention & control Intravitreal Injections Medicine Medicine & Public Health Ophthalmology Phacoemulsification Rabbits Retina - pathology Retinal Detachment - pathology Retinal Detachment - prevention & control Retinal Disorders Transforming Growth Factor beta - antagonists & inhibitors Vitrectomy Vitreoretinopathy, Proliferative - prevention & control |
| title | The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T09%3A46%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20novel%20use%20of%20decorin%20in%20prevention%20of%20the%20development%20of%20proliferative%20vitreoretinopathy%20(PVR)&rft.jtitle=Graefe's%20archive%20for%20clinical%20and%20experimental%20ophthalmology&rft.au=Nassar,%20Khaled&rft.date=2011-11-01&rft.volume=249&rft.issue=11&rft.spage=1649&rft.epage=1660&rft.pages=1649-1660&rft.issn=0721-832X&rft.eissn=1435-702X&rft_id=info:doi/10.1007/s00417-011-1730-9&rft_dat=%3Cproquest_cross%3E2496639231%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=900769164&rft_id=info:pmid/21735240&rfr_iscdi=true |